As of 2025-11-08, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is (29.88) USD. This relative valuation is based on P/E multiples. With the latest stock price at 442.70 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -106.7%.
The range of the Relative Valuation is (35.05) - (34.81) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 5.2x - 14.3x | 9.8x |
| Forward P/E multiples | 14.4x - 15.2x | 14.8x |
| Fair Price | (35.05) - (34.81) | (29.88) |
| Upside | -107.9% - -107.9% | -106.7% |
| Date | P/E |
| 2025-11-07 | -181.86 |
| 2025-11-06 | -180.95 |
| 2025-11-05 | -178.51 |
| 2025-11-04 | -173.96 |
| 2025-11-03 | -178.31 |
| 2025-10-31 | -187.34 |
| 2025-10-30 | -184.68 |
| 2025-10-29 | -197.83 |
| 2025-10-28 | -195.50 |
| 2025-10-27 | -196.60 |
| 2025-10-24 | -190.37 |
| 2025-10-23 | -190.61 |
| 2025-10-22 | -190.98 |
| 2025-10-21 | -194.72 |
| 2025-10-20 | -201.79 |
| 2025-10-17 | -197.87 |
| 2025-10-16 | -197.62 |
| 2025-10-15 | -193.18 |
| 2025-10-14 | -192.81 |
| 2025-10-13 | -191.00 |
| 2025-10-10 | -189.15 |
| 2025-10-09 | -187.71 |
| 2025-10-08 | -185.14 |
| 2025-10-07 | -188.79 |
| 2025-10-06 | -185.68 |
| 2025-10-03 | -187.47 |
| 2025-10-02 | -189.37 |
| 2025-10-01 | -189.23 |
| 2025-09-30 | -187.32 |
| 2025-09-29 | -183.83 |
| 2025-09-26 | -183.38 |
| 2025-09-25 | -184.68 |
| 2025-09-24 | -188.30 |
| 2025-09-23 | -186.67 |
| 2025-09-22 | -188.52 |
| 2025-09-19 | -186.32 |
| 2025-09-18 | -185.75 |
| 2025-09-17 | -185.57 |
| 2025-09-16 | -189.47 |
| 2025-09-15 | -189.43 |
| 2025-09-12 | -191.39 |
| 2025-09-11 | -192.49 |
| 2025-09-10 | -192.79 |
| 2025-09-09 | -198.06 |
| 2025-09-08 | -186.92 |
| 2025-09-05 | -185.68 |
| 2025-09-04 | -186.31 |
| 2025-09-03 | -183.80 |
| 2025-09-02 | -183.63 |
| 2025-08-29 | -183.42 |